Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
EDMONTON, Alberta–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company commi... Read more.
Aviation Capital Group Announces Delivery of One A321neo to Spirit Airlines
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–#acg–Aviation Capital Group LLC (“ACG”) announced the delivery of one new Airbus A321neo aircraft on... Read more.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of John Wiley & Sons, Inc. (WLY) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation... Read more.
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Advance Auto Parts (AAP)
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 8, 2023 deadline to file a lead p... Read more.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class acti... Read more.
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against DLocal Limited (DLO)
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 5, 2023 deadline to file a lead p... Read more.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has... Read more.
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
CHMP recommends approval for BRUKINSA plus obinutuzumab as a treatment for adult patients who have received at least two prior lines of therapy If approved, BRU... Read more.
Navigating the Dynamic US Telecommunications Market: Trends and Forecasts up to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “United States (US) Telecom Operators Country Intelligence Report” report has been added to ResearchAndMarket... Read more.
AM Best Revises Outlooks to Negative for Members of Pekin Insurance Group and Pekin Life Insurance Company
OLDWICK, N.J.–(BUSINESS WIRE)–#insurance—AM Best has revised the outlooks to negative from stable and affirmed the Financial Strength Rating (... Read more.
